A controversial American Academy of Dermatology (AAD) pilot program
that aims to boost the number of dermatology residencies using funding from
pharmaceutical companies and other sources has left some physicians questioning
the need for more dermatologists and the wisdom of allowing pharmaceutical
support for graduate medical education.
On November 12, 2004, the AAD announced the initiative, which will pool
money donated by the academy, pharmaceutical companies, and other interested
parties to fund 10 new dermatology residency slots for the July 2006 match.
In late January, the AAD board decided to expand the initiative to seek other
possible solutions to a perceived shortage such as the use of nurse practitioners
and other such staff or training for primary care physicians.
Kuehn BM. Pharmaceutical Industry Funding for Residencies Sparks Controversy. JAMA. 2005;293(13):1572-1580. doi:10.1001/jama.293.13.1572